Table 4.
Effect of the studied gene variants on clinical parameters in patients with COVID-19.
| Clinical parameters | Genetic variant |
Results of statistical analyses | |||||
|---|---|---|---|---|---|---|---|
|
SFTPB rs11130866 |
NR3C1 rs41423247 |
||||||
| CC | CT | TT | CC | CG | GG | ||
| Temperature 1d, °C | 37.6 ± 0.8 | 37.6 ± 0.8 | 37.8 ± 0.8 | 37.8 ± 0.9 | 37.5 ± 0.7 | 37.6 ± 0.8 | p > 0.05 |
| Temperature 2d, °C | 37.3 ± 0.6 | 37.3 ± 0.6 | 37.2 ± 0.6 | 37.3 ± 0.5 | 37.2 ± 0.6 | 37.4 ± 0.7 | p > 0.05 |
| Temperature 6d, °C | 36.8 ± 0.4 | 36.8 ± 0.5 | 37.0 ± 0.7 | 37.0 ± 0.5 | 36.8 ± 0.4 | 36.7 ± 0.5 | p > 0.05 |
| Respiratory rate 1d, per minute | 23.8 ± 3.7 | 22.8 ± 1.8 | 23.0 ± 2.0 | 23.6 ± 3.5 | 23.3 ± 2.2 | 22.2 ± 2.2 | p > 0.05 |
| Respiratory rate 3d, per minute | 23.4 ± 4.0 | 23.1 ± 2.0 | 22.3 ± 2.5 | 23.8 ± 3.9 | 22.9 ± 2.3 | 21.8 ± 1.5 | p > 0.05 |
| Respiratory rate 6d, per minute | 23.5 ± 3.1 | 23.2 ± 2.8 | 22.8 ± 2.2 | 23.6 ± 2.7 | 22.8 ± 3.0 | 23.8 ± 2.3 | p > 0.05 |
| SpO2/FiO2 1da, % | 183.2 ± 102.0 | 150.4 ± 57.2 | 173.07 ± 68.7 | 174.7 ± 81.2 | 159.2 ± 82.1 | 178.9 ± 71.3 | p > 0.05 |
| SpO2/FiO2 2da, % | 217.2 ± 130.8 | 195.3 ± 106.5 | 210.1 ± 131.7 | 196.5 ± 105.0 | 201.1 ± 116.0 | 238.0 ± 155.6 | p > 0.05 |
| SpO2/FiO2 6da, % | 235.4 ± 141.7 | 196.8 ± 123.5 | 225.3 ± 143.1 | 218.2 ± 119.5 | 219.1 ± 143.4 | 192.2 ± 139.8 | p > 0.05 |
| SOFA scale score 1da, in points | 3 [2–3] | 2 [2–2.5] | 2 [2–3] | 2 [2-2] | 2 [2–3] | 2.5 [2–3] | p > 0.05 |
| SOFA scale score 2da, in points | 3 [2–3] | 2 [2–3] | 2 [2–3] | 2 [2–3] | 2 [2–3] | 2.5 [2–3] | p > 0.05 |
| SOFA scale score 6da, in points | 3 [2–3] | 2 [2–3] | 2 [2–2.5] | 2 [2–3] | 2 [2–3] | 3 [2–3] | p > 0.05 |
| Glasgow coma scale score 1da, in points | 8 [7–8] | 8 [7–9] | 8 [7–9.5] | 8 [7–8.3] | 8 [6–9] | 8 [7–8] | p > 0.05 |
| Glasgow coma scale score 2da, in points | 8 [6–8.3] | 8 [7–9] | 9 [6.5–10] | 8 [7–8] | 8 [5.5–10] | 8 [6–9] | p > 0.05 |
| Glasgow coma scale score 6da, in points | 7.5 [5.3–8] | 8 [7–9] | 8.5 [5.8–13.5] | 8 [7–8] | 8 [4.3–9] | 8 [4.5–8] | p > 0.05 |
| Dose of glucocorticoids, mg/day | 6.3 ± 1.9 | 6.2 ± 1.5 | 6.9 ± 1.0 | 6.3 ± 1.8 | 6.0 ± 0.6 | 8.0 ± 2.8 | p > 0.05 |
| Duration of glucocorticoid therapy, days | 11.5 ± 6.7 | 11.0 ± 4.6 | 10.0 ± 5.7 | 13.8 ± 5.0 | 9.0 ± 5.0 | 11.5 ± 4.2 | p = 0.038 |
| Duration of ALV, days | 7.4 ± 6.0 | 5.0 ± 4.9 | 3.3 ± 2.6 | 5.8 ± 5.9 | 5.1 ± 4.8 | 6.3 ± 5.9 | p > 0.05 |
| Duration of oxygen therapy using oxygen mask, days | 6.1 ± 2.9 | 6.4 ± 4.0 | 5.2 ± 6.4 | 6.9 ± 4.1 | 5.4 ± 4.2 | 6.0 ± 4.0 | p > 0.05 |
| Total duration of oxygen support, days | 5.3 ± 7.1 | 9.0 ± 6.0 | 4.1 ± 6.2 | 10.6 ± 8.4 | 5.4 ± 4.2 | 4.2 ± 5.1 | p = 0.013 |
a
Values are presented as the median [25th–75th percentile]; ALV—artificial lung ventilation 1d, 2d, 6d—day.